Physiomics Past Earnings Performance
Past criteria checks 0/6
Physiomics's earnings have been declining at an average annual rate of -40.2%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 2.2% per year.
Key information
-40.2%
Earnings growth rate
-32.6%
EPS growth rate
| Life Sciences Industry Growth | 36.9% |
| Revenue growth rate | -2.2% |
| Return on equity | -67.2% |
| Net Margin | -70.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
It's Unlikely That Shareholders Will Increase Physiomics Plc's (LON:PYC) Compensation By Much This Year
Nov 15
Here's Why We Think Physiomics Plc's (LON:PYC) CEO Compensation Looks Fair
Nov 17Here's Why Shareholders Will Not Be Complaining About Physiomics Plc's (LON:PYC) CEO Pay Packet
Nov 16What Can We Conclude About Physiomics' (LON:PYC) CEO Pay?
Feb 08
Revenue & Expenses BreakdownBeta
How Physiomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | 0 | 0 | 0 |
| 30 Sep 23 | 1 | 0 | 0 | 0 |
| 30 Jun 23 | 1 | 0 | 0 | 0 |
| 31 Mar 23 | 1 | 0 | 0 | 0 |
| 31 Dec 22 | 1 | 0 | 0 | 0 |
| 30 Sep 22 | 1 | 0 | 0 | 0 |
| 30 Jun 22 | 1 | 0 | 0 | 0 |
| 31 Mar 22 | 1 | 0 | 0 | 0 |
| 31 Dec 21 | 1 | 0 | 0 | 0 |
| 30 Sep 21 | 1 | 0 | 0 | 0 |
| 30 Jun 21 | 1 | 0 | 0 | 0 |
| 31 Mar 21 | 1 | 0 | 0 | 0 |
| 31 Dec 20 | 1 | 0 | 0 | 0 |
| 30 Sep 20 | 1 | 0 | 0 | 0 |
| 30 Jun 20 | 1 | 0 | 0 | 0 |
| 31 Mar 20 | 1 | 0 | 0 | 0 |
| 31 Dec 19 | 1 | 0 | 0 | 0 |
| 30 Sep 19 | 1 | 0 | 0 | 0 |
| 30 Jun 19 | 1 | 0 | 0 | 0 |
| 31 Mar 19 | 1 | 0 | 0 | 0 |
| 31 Dec 18 | 1 | 0 | 0 | 0 |
| 30 Sep 18 | 1 | 0 | 0 | 0 |
| 30 Jun 18 | 1 | 0 | 0 | 0 |
| 31 Mar 18 | 0 | 0 | 0 | 0 |
| 31 Dec 17 | 0 | 0 | 0 | 0 |
| 30 Sep 17 | 0 | 0 | 0 | 0 |
| 30 Jun 17 | 0 | 0 | 0 | 0 |
| 31 Mar 17 | 0 | 0 | 0 | 0 |
| 31 Dec 16 | 0 | 0 | 0 | 0 |
| 30 Sep 16 | 0 | 0 | 0 | 0 |
| 30 Jun 16 | 0 | 0 | 0 | 0 |
| 31 Mar 16 | 0 | 0 | 0 | 0 |
| 31 Dec 15 | 0 | 0 | 0 | 0 |
| 30 Sep 15 | 0 | 0 | 0 | 0 |
| 30 Jun 15 | 0 | 0 | 0 | 0 |
| 31 Mar 15 | 0 | 0 | 0 | 0 |
| 31 Dec 14 | 0 | 0 | 0 | 0 |
| 30 Sep 14 | 0 | 0 | 0 | 0 |
| 30 Jun 14 | 0 | 0 | 0 | 0 |
| 31 Mar 14 | 0 | 0 | 0 | 0 |
| 31 Dec 13 | 0 | 0 | 0 | 0 |
| 30 Sep 13 | 0 | 0 | 0 | 0 |
| 30 Jun 13 | 0 | -1 | 0 | 0 |
Quality Earnings: PYC is currently unprofitable.
Growing Profit Margin: PYC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PYC is unprofitable, and losses have increased over the past 5 years at a rate of 40.2% per year.
Accelerating Growth: Unable to compare PYC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PYC is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (6.5%).
Return on Equity
High ROE: PYC has a negative Return on Equity (-67.15%), as it is currently unprofitable.